Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Center on Drug and Alcohol Research, University of Kentucky, Lexington, Kentucky, USA.
J Community Psychol. 2024 Nov;52(8):997-1014. doi: 10.1002/jcop.23029. Epub 2023 Mar 17.
The purpose of this qualitative study is to assess facilitating factors and barriers for medications to treat opioid use disorder (MOUD) initiation among justice-involved individuals in one rural Appalachian community, as well as how those factors may differ across the three types of Food and Drug Administration (FDA) approved medications. Qualitative interviews were conducted with rural justice-involved individuals (N = 10) with a history of opioid use in the target community. Overall, participants demonstrated knowledge of the different types of MOUD and their pharmacological properties, but limited overall health literacy around opioid use disorder and MOUD treatment. Treatment access was hampered by transportation, time burdens, and costs. Findings call for research into improving health literacy education, training, and resources to decrease stigma and increase access to MOUD, particularly in light of the ongoing opioid crisis. State policies also need to increase access to all FDA medications among justice-involved individuals, as well as supporting a care continuum from facility entry, release, and community re-entry.
本定性研究旨在评估农村阿巴拉契亚社区中涉及司法的个体开始使用治疗阿片类药物使用障碍（MOUD）药物的促进因素和障碍，以及这些因素如何因三种经美国食品和药物管理局（FDA）批准的药物而有所不同。对目标社区中有阿片类药物使用史的农村涉及司法的个体（N=10）进行了定性访谈。总体而言，参与者对不同类型的 MOUD 及其药理学特性有一定了解，但对阿片类药物使用障碍和 MOUD 治疗的整体健康素养有限。治疗的可及性受到交通、时间负担和费用的限制。研究结果呼吁开展研究，改善健康素养教育、培训和资源，以减少污名化，增加 MOUD 的可及性，特别是在持续的阿片类药物危机的背景下。州政策还需要增加涉及司法的个体对所有 FDA 药物的可及性，并支持从设施进入、释放和社区重新进入的护理连续性。
